Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade
Hepatitis C virus (HCV) infects both pediatric and adult populations and is an important cause of chronic liver disease worldwide. There are differences in the screening and management of HCV between pediatric and adult patients, which have been highlighted in this review. Direct-acting antiviral ag...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/14/1/11 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587774930190336 |
|---|---|
| author | Nanda Kerkar Kayla Hartjes |
| author_facet | Nanda Kerkar Kayla Hartjes |
| author_sort | Nanda Kerkar |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) infects both pediatric and adult populations and is an important cause of chronic liver disease worldwide. There are differences in the screening and management of HCV between pediatric and adult patients, which have been highlighted in this review. Direct-acting antiviral agents (DAA) have made the cure of HCV possible, and fortunately, these medications are approved down to three years of age. However, treatment in the pediatric population has its own set of challenges. The World Health Organization (WHO) has made a pledge to eliminate HCV as a public health threat by 2030. Despite this, HCV continues to remain a global health burden, leading to cirrhosis as well as hepatocellular carcinoma, and is a reason for liver transplantation in the adult population. Although rare, these complications can also affect the pediatric population. A variety of new technologies t have become available in the current era and can advance our understanding of HCV are discussed. Artificial intelligence, machine learning, liver organoids, and liver-on-chip are some examples of techniques that have the potential to contribute to our understanding of the disease and treatment process in HCV. Despite efforts over several decades, a successful vaccine against HCV has yet to be developed. This would be an important tool to help in worldwide efforts to eliminate the virus. |
| format | Article |
| id | doaj-art-c016564032204390b006fd0eb9cd2c86 |
| institution | Kabale University |
| issn | 2076-0817 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj-art-c016564032204390b006fd0eb9cd2c862025-01-24T13:44:35ZengMDPI AGPathogens2076-08172024-12-011411110.3390/pathogens14010011Hepatitis C Virus–Pediatric and Adult Perspectives in the Current DecadeNanda Kerkar0Kayla Hartjes1Massachusetts General Brigham for Children, 175 Cambridge Street, Boston, MA 02114, USAMassachusetts General Brigham for Children, 175 Cambridge Street, Boston, MA 02114, USAHepatitis C virus (HCV) infects both pediatric and adult populations and is an important cause of chronic liver disease worldwide. There are differences in the screening and management of HCV between pediatric and adult patients, which have been highlighted in this review. Direct-acting antiviral agents (DAA) have made the cure of HCV possible, and fortunately, these medications are approved down to three years of age. However, treatment in the pediatric population has its own set of challenges. The World Health Organization (WHO) has made a pledge to eliminate HCV as a public health threat by 2030. Despite this, HCV continues to remain a global health burden, leading to cirrhosis as well as hepatocellular carcinoma, and is a reason for liver transplantation in the adult population. Although rare, these complications can also affect the pediatric population. A variety of new technologies t have become available in the current era and can advance our understanding of HCV are discussed. Artificial intelligence, machine learning, liver organoids, and liver-on-chip are some examples of techniques that have the potential to contribute to our understanding of the disease and treatment process in HCV. Despite efforts over several decades, a successful vaccine against HCV has yet to be developed. This would be an important tool to help in worldwide efforts to eliminate the virus.https://www.mdpi.com/2076-0817/14/1/11HCVchildrenimmune responseepidemiologyvaccineaccess to care |
| spellingShingle | Nanda Kerkar Kayla Hartjes Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade Pathogens HCV children immune response epidemiology vaccine access to care |
| title | Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade |
| title_full | Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade |
| title_fullStr | Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade |
| title_full_unstemmed | Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade |
| title_short | Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade |
| title_sort | hepatitis c virus pediatric and adult perspectives in the current decade |
| topic | HCV children immune response epidemiology vaccine access to care |
| url | https://www.mdpi.com/2076-0817/14/1/11 |
| work_keys_str_mv | AT nandakerkar hepatitiscviruspediatricandadultperspectivesinthecurrentdecade AT kaylahartjes hepatitiscviruspediatricandadultperspectivesinthecurrentdecade |